Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107444 | 0.90 | GCK (0.62) | GCKRARARARBLMNAHPGD | |
| SCHEMBL1107685 | 0.90 | GCK (0.62) | GCKRARARARBLMNAHPGD | |
| SCHEMBL2086735 | 0.90 | GCK (0.62) | GCKRARARARBLMNAHPGD | |
| SCHEMBL2656262 | 0.88 | LMNA (0.56) | GCKRARARARBLMNAHPGD | |
| SCHEMBL2086439 | 0.87 | GCK (0.66) | GCKRARARARBCNR2IGLV6-57 | |
| SCHEMBL27740832 | 0.87 | GCK (0.66) | GCKRARARARBCNR2IGLV6-57 | |
| SCHEMBL1427184 | 0.85 | GCK (0.61) | GCKLMNAHPGD | |
| SCHEMBL1107694 | 0.82 | CA1 (0.50) | LMNACA1CA2TSHR | |
| SCHEMBL1261462 | 0.82 | GCK (0.57) | GCKLMNATSHRPPARA | |
| SCHEMBL1796232 | 0.81 | HSD17B10 (0.47) | GCKLMNACA1CA2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | GCK 1/4885RARA 2660/4885RARB 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.